CAMZYOS Extends Cardiac-Myosin Inhibition to Adolescents
FDA expanded CAMZYOS to symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms, making mavacamten the first approved therapy specifically for pediatric obstructive HCM. In the randomized Phase 3…
